epitopesonCYP2D6arerecognizedbyliver/kidneymicrosomalanti2bodies[J].Gastroenterology,1995,108∶470-6.[10]MuratoriL,LenziM,MaY,etal.Heterogeneityofliver/kidneymicrosomalantibodytype1inautoimmunehepatitisandhepatitisCvirusrelatedliverdisease[J].Gut,1995,37∶406-12.[11]DesmetVJ,GerberM,HoofnagleJH,etal.Classificationofchron2ichepatitis:diagnosis,gradingandstaging[J].Hepatology,1994,19∶1513-20.[12]RobinMA,MaratratM,LoeperJ,etal.CytochromeP4502Bfol2lowsavesicularroutetotheplasmamembraneinculturedrathepato2cytes[J].Gastroenterology,1995,108∶1110-23.[13]StrassburgCP,ObermayerStraubP,AlexB,etal.Autoantibodiesagainstglucuronosyltransferasesdifferbetweenviralhepatitisandau2toimmunehepatitis[J].Gastroenterology,1996,111∶1576-86.[14]MannsMDGriffinKJ,QuattrochiLC,etal.Identificationofcyto2chromeP450IA2asahumanautoantigen[J].ArchBiochemBio2phys,1990,280∶229-32.[15]MuratoriL,CataletaM,MuratoriP,etal.Liver/kidneymicrosom2alantibodytype1andlivercytosolanti-bodytype1concentrationsintype2autoimmunehepatitis[J].Gut,1998,42∶721-6.[16]LohseAW,GerkemG,MohrH,etal.Relationbetweenautoim2munehepatitisandviralhepatitis:clinicalandserologicalcharacteris2ticsin859patients[J].ZGastroenterol,1995,33∶527-33.[17]CzajaAJ,MannsMP.Thevalidityandimportanceofsubtypesinautoimmunehepatitis:apointofview[J].AmJGastroenterol,1995,90∶1206-11.[18]WiesI,HenningerJ,BrunnerS,etal.Cloningofthetarget-anti2genofantibodiestosolubleliverantigen:identificationofanovel50kDaproteinwithtwosplice-variants[Abstract].Hepatol,1998,28(Suppl.4)∶190A.[19]MulderAH,HorstG,HaagsmaEB,etal.Prevalenceandcharac2terizationofneutrophilcytoplaasmicantibodiesinautoimmuneliverdiseases.Hepatology,1993,17∶411-7.[20]SummerskillWHJ,KormanMG,AmmonHV,etal.Prednisoneforchronicactiveliverdisease:dosetitration,standarddoseandcombi2nationwithazathioprinecompound[J].Gut,1975,16∶876-83.[21]CzajzAJ.Drugtherapyinthemanagementoftype1autoim-munehepatitis[J].Drugs,1999,57∶49-68.[22]HombergJC,AndreC,AbuafN.Anewanti-liver/kidney-mi2crosomeantibody(anti-LKM2)intienilicinducedhepatitis[J].ClinExpImmunol,1984,55∶561-70.[23]McGinnisMD,ConradMP,BouwensAGM,etal.Automated,sol2id-phasesequencingofDRBregiongenesT7sequencingchemistryanddye-labeledprimers[J].TissueAntigens,1995,46∶173-9.[24]CrosP,AllibertP,MandrandB,etal.OligonucleotidegenotypingofHLApolymorphismonmicrotitreplates[J].TheLancet,1992,340∶870-3.氧化应激与肝纤维化张晓岚,王占魁,姜慧卿(河北医科大学第二医院消化科,河北石家庄050000)收稿日期:2006-05-30修订日期:2006-07-05作者简介:张晓岚(1963—),女,博士,主任医师、教授,主要从事肝纤维化发病机制方面的研究。【中图分类号】R57512【文献标识码】A【文章编号】1001-5256(2007)03-0226-04肝纤维化的主要病理改变是细胞外基质(ECM)成分的过度合成与异常沉积,肝星状细胞(HSC)活化、增殖是肝纤维化形成的中心环节[1]。诸多肝损伤因素在其致病过程中均不同程度地伴有氧化应激(oxidativestress,OS),这些病因不祛除、长期作用于肝脏即可导致肝纤维化乃至肝硬化。近年来,氧化应激与肝纤维化,特别是HSC活化的关系日益受到关注[2,3]。本文就氧化应激在不同病因所致肝纤维化中的作用及其机制作一综述。1氧化应激概述氧化应激是指机体或细胞内活性氧(reactiveoxygenspecies,ROS)过度产生和/或抗氧化防御功能减弱,引起两者之间平衡严重破坏,造成组织、细胞损伤的一种状态。ROS包括氧自由基及其歧化产物,如超氧阴离子自由基(O-2.)、氢化氧基(.HO2)、过氧化氢(H2O2)、羟自由基(.OH)及单线态氧(’O2)等;其他氧化物还有次氯酸、脂质过氧化物、丙二醛(MD...
